leukaemia
NICE issues draft guidance rejecting Abbvie’s Venclyxto in chronic lymphocytic leukaemia
October 26, 2018Medical Communications, Sales and Marketing AbbVie, NHS, NICE, leukaemia, pharma, venetoclax
It’s bad news for patients in the UK affected by chronic lymphocytic leukaemia (CLL) as the National Institute of Health …
NICE recommends Pfizer’s Mylotarg combo in CD33-positive acute myeloid leukaemia
October 8, 2018Sales and Marketing Mylotarg, NICE, Pfizer, acute myeloid leukaemia, leukaemia, pharma
NICE has revealed its recommendation for Pfizer’s Mylotarg (gemtuzumab ozogamicin) to be used on the NHS in the treatment of …
20 year old man died after leukaemia cell was accidently mixed into CAR T therapy
October 2, 2018Manufacturing and Production CAR T, CAR-T, Cancer, Kymriah, Novartis, leukaemia, oncology
A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that …
NICE rejects CAR-T therapy Kymriah for DLBCL in adults
September 19, 2018Research and Development CAR T, CAR-T, Kymriah, NICE, Novartis, leukaemia
The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with …
FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia (HCL)
September 17, 2018Sales and Marketing AstraZeneca, HCL, Lumoxiti, leukaemia, rare diseases
AstraZeneca’s Lumoxiti has been approved for use for the treatment of relapsed or refractory hairy cell leukemia (HCL)in adults who …
Jazz Pharma’s acute myeloid leukaemia drug scores EU approval
August 29, 2018Research and Development, Sales and Marketing Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, leukaemia, pharma
Jazz Pharmaceuticals has revealed that its advanced liposomal formulation Vyxeos has received approval from the European Commission for the treatment …
NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients
August 10, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma
The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …
NICE recommends Pfizer’s Besponsa in rare leukaemia following review
August 9, 2018Sales and Marketing NICE, Pfizer, leukaemia, pharma
Pfizer has revealed that NICE has finally decided to recommend its CD22-targeting monoclonal antibody Besponsa (inotuzumab ozogamicin) in the treatment …
The cause of the most common form of childhood cancer found
May 22, 2018Manufacturing and Production, Research and Development biotech, drugs, leukaemia, pharma, pharmaceutical
Professor Mel Greaves, of The Institute of Cancer Research, has spent 30 years uncovering what is behind the mysterious rise …
Porton Biopharma opens new leukaemia drug production facility
May 1, 2018Manufacturing and Production Porton Biopharma, leukaemia, pharma
Porton Biopharma Limited (PBL) has officially opened the doors of its new fermentation facility. John Glen, MP for Salisbury and …
FDA expands indication of Teva’s Trisenox for acute promyelocytic leukaemia
January 16, 2018Manufacturing and Production, Sales and Marketing FDA, Teva, acute promyelocytic leukaemia, leukaemia, pharma
Teva has announced that its Trisenox (arsenic trioxide) injection has been awarded US approval from the FDA in combination with …
Pfizer’s Bosulif scores US green light in leukaemia sub-type
December 21, 2017Sales and Marketing FDA, Pfizer, bosulif, leukaemia, leukemia, pharma
Pfizer has revealed that its tyrosine kinase inhibitor Bosulif (bosutinib) has been awarded marketing authorisation from the FDA in the …
Blood cancer patients over 75 are significantly underrepresented in clinical trials, study finds
December 13, 2017Research and Development FDA, blood cancer, leukaemia, lymphoma, myeloid leukaemia, pharma
The FDA’s first comprehensive analysis of clinical trial enrolment in older patients with blood cancers has revealed that the population …
Novartis nets first acute myeloid leukaemia approval in Canada, but NICE says no
December 6, 2017Research and Development, Sales and Marketing Canada, NICE, Novartis, Rydapt, UK, acute myeloid leukaemia, leukaemia, pharma
Novartis is celebrating the news that its drug Rydapt (midostaurin) has been awarded marketing approval in Canada for the treatment …
Roche and AbbVie’s leukaemia combo smashes Phase 3 endpoint
September 19, 2017Manufacturing and Production, Research and Development AbbVie, Rituxan, Roche, Venclexta, Venclyxto, leukaemia, pharma, pharmaceutical
Venclexta/Venclyxto (venetoclax), Roche and AbbVie’s oral B-cell lymphoma-2 (BCL-2) inhibitor, successfully met its primary endpoint in Phase 3 trials, providing …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
